榮峰

[摘要]目的 探討地塞米松注射液在呼吸道感染患者中的應(yīng)用效果。方法 選取我院2016年5月～2018年5月收治的120例呼吸道感染患者作為研究對(duì)象，按照不同治療方法分為治療組（60例）與對(duì)照組（60例）。治療組采用對(duì)癥治療聯(lián)合地塞米松注射液治療，對(duì)照組僅采用單純對(duì)照治療。比較兩組的體溫恢復(fù)情況、不良反應(yīng)發(fā)生情況、生活質(zhì)量SF-36評(píng)分。結(jié)果 治療組的體溫恢復(fù)時(shí)間、治療時(shí)間均短于對(duì)照組，差異有統(tǒng)計(jì)學(xué)意義（P<0.05）;治療組的不良反應(yīng)總發(fā)生率高于對(duì)照組，差異有統(tǒng)計(jì)學(xué)意義（P<0.05）;治療組治療后的生活質(zhì)量SF-36評(píng)分高于對(duì)照組，差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 臨床對(duì)呼吸道感染患者采用地塞米松注射液治療，雖可加速體溫恢復(fù)正常，從而提高生活質(zhì)量，但值得注意的是，其不良反應(yīng)發(fā)生率較高，建議謹(jǐn)慎使用。

[關(guān)鍵詞]呼吸道感染;地塞米松注射液;不良反應(yīng);對(duì)癥治療

[中圖分類號(hào)] R56? ? ? ? ? [文獻(xiàn)標(biāo)識(shí)碼] A? ? ? ? ? [文章編號(hào)] 1674-4721（2019）2（a）-0048-03

[Abstract] Objective To explore the application effect of Dexamethasone Injection in patients with respiratory tract infection. Methods A total of 120 patients with respiratory tract infection admitted to our hospital from May 2016 to May 2018 were selected as study subjects， and divided into the treatment group （60 cases） and the control group （60 cases） according to different treatment methods. Symptomatic treatment combined with Dexamethasone Injection was used in the treatment group， while the control group was only treated with simple control. Temperature recovery， adverse reactions， and quality of life SF-36 scores were compared between the two groups. Results The temperature recovery time and treatment time of the treatment group were shorter than those of the control group， and the differences were statistically significant （P<0.05）. The total incidence rate of adverse reaction of the treatment group was higher than that of the control group， and the difference was statistically significant （P<0.05）. Quality of life SF-36 score in the treatment group after treatment was higher than that in the control group， the difference was statistically significant （P<0.05）. Conclusion Dexamethasone Injection can accelerate the recovery of body temperature and improve the quality of life in patients with respiratory tract infection. However， it is worth noting that the adverse reaction rate is relatively high and it is recommended to be used cautiously.

[Key words] Respiratory tract infection; Dexamethasone Injection; Adverse reactions; Symptomatic treatment

上呼吸道感染是指咽喉部、鼻腔引發(fā)急性炎癥所致，具有較高的患病率，特別是在流行性感染高發(fā)時(shí)段或者是春、冬兩季[1]。該病的傳染性較強(qiáng)，若未能得到及時(shí)且有效控制，則容易產(chǎn)生諸多嚴(yán)重并發(fā)癥，對(duì)患者正常生活、工作水平產(chǎn)生影響，因此，加強(qiáng)早期預(yù)防與控制呼吸道感染病癥對(duì)加速患者早日恢復(fù)身體健康具有重大積極意義。目前，本病臨床中常用常規(guī)抗感染治療，雖具有一定成效，但效果不明顯。地塞米松屬于一種糖皮質(zhì)激素類藥物，可發(fā)揮抗休克、抗炎、抗過敏等藥物作用[2-3]。但多項(xiàng)臨床實(shí)踐顯示，該藥的不良反應(yīng)較多，受到醫(yī)學(xué)界高度重視。本研究選取我院收治的呼吸道感染患者作為研究對(duì)象，旨在探討地塞米松注射液治療的臨床現(xiàn)實(shí)意義，并評(píng)價(jià)治療后的不良反應(yīng)發(fā)生情況，現(xiàn)報(bào)道如下。

1資料與方法

1.1一般資料

隨機(jī)選取2016年5月～2018年5月我院收治的120例呼吸道感染患者作為研究對(duì)象，依照不同治療方案分為治療組和對(duì)照組，各60例。治療組中，男34例，女26例;年齡20～75歲，平均（43.11±6.38）歲。對(duì)照組中，男35例，女25例;年齡18～73歲，平均（43.05±6.13）歲。所有患者均伴有程度不一的咳嗽、咳痰、發(fā)熱、鼻塞等臨床病癥。兩組的一般資料比較，差異無統(tǒng)計(jì)學(xué)意義（P>0.05），具有可比性。納入標(biāo)準(zhǔn)：①確診為呼吸道感染者;②積極配合本次臨床試驗(yàn)者;③無其他嚴(yán)重并發(fā)癥者;④所有患者均已簽署知情同意書，且經(jīng)醫(yī)院醫(yī)學(xué)倫理委員會(huì)審核批準(zhǔn)。排除標(biāo)準(zhǔn)：①患有嚴(yán)重心血管疾病者;②年齡<15周歲者;③患有嚴(yán)重精神類疾病者。